- Home
- BTU vs RARE Comparison
BTU vs RARE Comparison
Compare BTU & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTU | RARE |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.2B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BTU | RARE |
|---|---|---|
| Price | $28.35 | $36.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $26.71 | ★ $85.20 |
| AVG Volume (30 Days) | ★ 2.6M | 1.4M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,962,300,000.00 | $630,598,000.00 |
| Revenue This Year | N/A | $19.09 |
| Revenue Next Year | $19.30 | $20.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.63 |
| 52 Week Low | $9.61 | $25.81 |
| 52 Week High | $35.99 | $49.19 |
Technical Indicators
Market Signals| Indicator | BTU | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 62.29 |
| Support Level | $27.51 | $35.65 |
| Resistance Level | $30.29 | $36.74 |
| Average True Range (ATR) | 1.40 | 1.38 |
| MACD | 0.15 | 0.15 |
| Stochastic Oscillator | 58.33 | 55.94 |
Price Performance
Historical ComparisonAbout BTU Peabody Energy Corporation
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan and other regions.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.